Literature DB >> 23460711

Geriatric factors predict chemotherapy feasibility: ancillary results of FFCD 2001-02 phase III study in first-line chemotherapy for metastatic colorectal cancer in elderly patients.

Thomas Aparicio1, Jean-Louis Jouve, Laurent Teillet, Dany Gargot, Fabien Subtil, Valérie Le Brun-Ly, Jacques Cretin, Christophe Locher, Olivier Bouché, Gilles Breysacher, Jacky Charneau, Jean-François Seitz, Mohamed Gasmi, Laetitia Stefani, Mohamed Ramdani, Thierry Lecomte, Emmanuel Mitry.   

Abstract

PURPOSE: Elderly patients form a heterogeneous population. Evaluation of geriatric factors may help evaluate a patient's health status to better adapt treatment. PATIENTS AND METHODS: Elderly patients with previously untreated metastatic colorectal cancer (mCRC) were randomly assigned to receive fluorouracil (FU) -based chemotherapy either alone or in combination with irinotecan (IRI) in the Fédération Francophone de Cancérologie Digestive (FFCD) 2001-02 study. Sites participating in the geriatric substudy completed geriatric screening tools to perform prognostic factor analyses for treatment safety during the first 4 months after treatment initiation.
RESULTS: The geriatric score was calculated in 123 patients (44%). Median age was 80 years (range, 75 to 91 years). The Charlson comorbidity index was ≤ 1 in 75%, Mini-Mental State Examination (MMSE) score was ≤ 27/30 in 31%, and Instrumental Activities of Daily Living (IADL) showed impairment in 34% of the patients. Seventy-one patients (58%) had grade 3 to 4 toxicity, 41 (33%) had a dose-intensity reduction of more than 33%, and 54 (44%) had at least one unexpected hospitalization during the first 4 months after starting treatment. In multivariate analysis, significant predictive factors for grade 3-4 toxicity were IRI arm (odds ratio [OR], 5.03), MMSE ≤ 27/30 (OR, 3.84), and impaired IADL (OR, 4.67); for dose-intensity reduction of > 33%, the significant predictive factors were alkaline phosphates > 2 × upper limit of normal (OR, 4.16) and IRI arm (OR, 6.85); and for unexpected hospitalization, significant predictive factors were MMSE ≤ 27/30 (OR, 4.56) and Geriatric Depression Scale ≤ 2 (OR, 5.52).
CONCLUSION: Geriatric factors (MMSE and IADL) are predictive of severe toxicity or unexpected hospitalization (MMSE) in a randomized prospective phase III study in mCRC. These results suggest that cognitive function and autonomy impairment should be taken into account when choosing a regimen for chemotherapy.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23460711     DOI: 10.1200/JCO.2012.42.9894

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  55 in total

1.  Outcomes of Elderly Patients with Advanced Soft Tissue Sarcoma Treated with First-Line Chemotherapy: A Pooled Analysis of 12 EORTC Soft Tissue and Bone Sarcoma Group Trials.

Authors:  Eugenie Younger; Saskia Litière; Axel Le Cesne; Olivier Mir; Hans Gelderblom; Antoine Italiano; Sandrine Marreaud; Robin Lewis Jones; Alessandro Gronchi; Winette T A van der Graaf
Journal:  Oncologist       Date:  2018-04-12

2.  Assessment of solid cancer treatment feasibility in older patients: a prospective cohort study.

Authors:  Marie Laurent; Elena Paillaud; Christophe Tournigand; Philippe Caillet; Aurélie Le Thuaut; Jean-Léon Lagrange; Olivier Beauchet; Hélène Vincent; Muriel Carvahlo-Verlinde; Stéphane Culine; Sylvie Bastuji-Garin; Florence Canouï-Poitrine
Journal:  Oncologist       Date:  2014-02-25

3.  Age-related changes in nanoparticle albumin-bound paclitaxel pharmacokinetics and pharmacodynamics: influence of chronological versus functional age.

Authors:  Arti Hurria; M Suzette Blanchard; Timothy W Synold; Joanne Mortimer; Cathie T Chung; Thehang Luu; Vani Katheria; Arnold J Rotter; Carol Wong; Anthony Choi; Tao Feng; Rupal Ramani; Caroline M Doan; Jaycen Brown; George Somlo
Journal:  Oncologist       Date:  2014-12-09

4.  Cost-effectiveness analysis of capecitabine plus bevacizumab versus capecitabine alone in elderly patients with previously untreated metastatic colorectal cancer from Chinese societal perspective.

Authors:  P-F Zhang; F Wen; J Zhou; J-X Huang; K-X Zhou; Q-J Wu; X-Y Wang; M-X Zhang; W-T Liao; Q Li
Journal:  Clin Transl Oncol       Date:  2019-05-06       Impact factor: 3.405

5.  A Clinical Prediction Model to Assess Risk for Chemotherapy-Related Hospitalization in Patients Initiating Palliative Chemotherapy.

Authors:  Gabriel A Brooks; Ankit J Kansagra; Sowmya R Rao; James I Weitzman; Erica A Linden; Joseph O Jacobson
Journal:  JAMA Oncol       Date:  2015-07       Impact factor: 31.777

Review 6.  Treatment of colorectal cancer in the elderly.

Authors:  Monica Millan; Sandra Merino; Aleidis Caro; Francesc Feliu; Jordi Escuder; Tani Francesch
Journal:  World J Gastrointest Oncol       Date:  2015-10-15

Review 7.  Cognitive effects of cancer systemic therapy: implications for the care of older patients and survivors.

Authors:  Jeanne S Mandelblatt; Paul B Jacobsen; Tim Ahles
Journal:  J Clin Oncol       Date:  2014-07-28       Impact factor: 44.544

8.  Challenges of conducting a prospective clinical trial for older patients: Lessons learned from NCCTG N0949 (alliance).

Authors:  Nadine J McCleary; Joleen Hubbard; Michelle R Mahoney; Jeffrey A Meyerhardt; Daniel Sargent; Alan Venook; Axel Grothey
Journal:  J Geriatr Oncol       Date:  2017-09-13       Impact factor: 3.599

9.  Factors Associated With Unplanned Hospitalizations Among Patients With Nonmetastatic Colorectal Cancers Intended for Treatment in the Ambulatory Setting.

Authors:  Kristen L Fessele; Matthew J Hayat; Deborah K Mayer; Robert L Atkins
Journal:  Nurs Res       Date:  2016 Jan-Feb       Impact factor: 2.381

Review 10.  How to select the optimal treatment for first line metastatic colorectal cancer.

Authors:  Alexander Stein; Carsten Bokemeyer
Journal:  World J Gastroenterol       Date:  2014-01-28       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.